Truist initiated coverage of Teva (TEVA) with a Buy rating and $25 price target Teva’s dual focus on cultivating its high-margin brands while strengthening generics continues to de-risk the topline and margin profile, says the analyst, who sees management executing well against the company’s “Pivot to Growth” plan. The firm sees potential line of sight to 30% operating margin by 2027, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA: